



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

Human Vaccines Project Europe Annual Report 2021

General

On January 21, 2019, the Human Vaccines Project Europe was incorporated and established as a foundation in The Netherlands.

Name: Stichting Human Vaccines Project Europe
Chamber of commerce registration number (KvK): 73750805
RISN (fiscal information number): 859651551

Address: Stakman Bossestraat 78, 2203GL Noordwijk, The Netherlands
Email: fvandenboom@humanvaccinesproject.org
jme@procontrol.nl

Tel: +31 651 241 549 | +31 619288009

Goals and main activities of the Stichting

The purpose of the European Program is to contribute to the overall objective of the Human Vaccines Project to decode the human immune system and to accelerate the development of vaccines, immunotherapies and diagnostics to prevent, treat and cure important diseases.

The Stichting will focus on outreach, advocacy, fundraising, creating partnerships and consortia to shape and strengthen the European contribution to the global research program by:

- Establishing a network of leading European centers for human immunology and vaccinology networks centers and connecting them to the mission and activities of the Human Vaccines Project.
- Mobilizing financial support from the public, private and philanthropic sector.
- Advocating for scientific prioritization of the decoding of the immunome.
- Working together with government institutions, academia, industry and non-state actors – building champions and powerful alliances.

Board members per 31 December 2021

Wayne C. Koff, Ph.D. (Chair)
Ted Schenkelberg, MBA/MPH (Secretary)
Jeroen van der Meer, M.Sc. (Treasurer)
Jaap Goudsmit, M.D./Ph.D., emiritus

Remuneration policy

The members of the board receive no remuneration for their work. They are entitled to reimbursement of the costs incurred by them in the performance of their duties.

Persons who are employed or employed for the benefit of the foundation can not be appointed as a member of the board.

Salary of staff is determined by the Board and will meet standards set by the Dutch government.



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

Board's Annual Report 2021

SARS-CoV-2

The SARS-CoV-2 pandemic continued to have a significant impact on the implementation of the 2021 work plan. It was virtually impossible to have face to face meetings, and globally the priority of public and private sector was on responding to the pandemic. Wherever possible, HVPE continued to advocate for the HVP mission and its pillar programs: the Human Immunomics Initiative (HII), the Covid Vaccine Initiative (CVI) and the Newborn Immunity Initiative (now: the Born Strong Initiative), and continued within the given constraints to implement its activities.

Priorities

In 2021, outreach activities in Europe involved multiple countries with a particular focus on Germany, The Netherlands and the European Commission. Activities in other countries were opportunity based.

The Netherlands

In addition to its continuing contribution to the “Trusted World of Corona” (TWOC) project¹ <https://www.health-holland.com/project/2020/trusted-world-of-corona>, HVPE engaged very actively in the preparation of a proposal to the Dutch National Growth Fund (NGF). Unfortunately the proposal was not taken into consideration for procedural reasons. However, working together with academia, industry, and government officials has significantly contributed to the visibility of HVPE.

Buidling upon the already existing realtionships with Erasmus University and the R-studies, a proposal was submitted to the Leducq Foundation. Unfortunately, the proposal did not quite fit the criteria of the call.

Germany

In Gemany HVPE through its partner, Looping Group continued to reach out to government, parliaments, foundations, private sector, and High Net Worth Individuals. These include the Bavarian Ministry of Science, Ministry of Science Hamburg, Ministry of economic cooperation and development;

Due to COVID-19 a virtual meeting on the Born Strong Initiative was postponed.

Looping Group also reached out to multiple foundations across Europe (Sweden, Denmark, Spain, Switzerland).

¹ The Trusted World of Corona (TWOC) is a user friendly, trustworthy information platform that is permanently updated with scientific data & information and real world, clinical observations on Corona. The consortium consists of 13 partners, including academic, research institutes and companies (including ICT and Pharma). The benefits will include better use of treatments, faster development of vaccines and a clearer view on factors that may negatively affect the outcomes of a COVID-19 infection and other future virus outbreaks. The basis for the research service provided by TWOC is mined data from literature, real world observations (mostly clinical but also self-reporting in COVID-19 apps), and outcomes from intervention trials concerning the worldwide pandemic of COVID-19.



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

European Commission

HVPE is the leader of Work Package 8 (WP8) of the INCENTIVE project (Indo-European Consortium for Next Generation Influenza Vaccine Innovation). Accomplishments in 2021 included the development of questionnaires and semi-structured interviews; identifying experts in Europe and India that can advise on WP8 tasks and deliverables; development of the discrete choice experiment (DCE) protocol; submitting the DCE protocol for ethical and regulatory approval in the clinical trials site in India and two cohort studies in India; finalizing the tender process for implementing a FAIR data architecture; organizing a Rapid Metadata for Machines (M4M).

HVP also was a partner in the development of a number of proposals to the European Commission:
Repurvax: Rejected
AGE-Vax: Under Review.

Conversations were also initiated with the kENUP foundation.



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

2021 Financial Report

General

Incorporation foundation

The deed of incorporation of Stichting Human Vaccines Project Europe, executed by mr. Guido Tjado Tjadens, civil law notary, shows that Stichting Human Vaccines Project Europe, a foundation, was incorporated on the January 21st. 2019.

Result

Analysis of the result

	<u>2021</u>
	€
Benefits	<u>81.300</u>
Expenses of employee benefits	50.280
Other operating expenses	<u>102.377</u>
Total of sum of expenses (B)	<u><u>152.657</u></u>
Total of net result (A-B)	<u><u>-71.357</u></u>



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

Financial position

To provide insight in the development of the financial position of the Company we provide you with the following statements. These are based on the information from the annual report. Hereafter we provide you with the balance sheet as at 31 December 2022 in an abridged form.

Financial structure	<u>31-12-2021</u>	
	€	%
Assets		
Receivables	-	-
Cash and cash equivalents	<u>205.373</u>	<u>100,0</u>
<u>205.373</u>	<u>100,0</u>	
Equity and liabilities		
Net assets	203.180	98,9
Short-term liabilities	<u>2.193</u>	<u>1,1</u>
<u>205.373</u>	<u>100,0</u>	
Analysis of the financial position		
<u>31-12-2021</u>		
€		
Available on short term		
Receivables	-	
Cash and cash equivalents	<u>205.373</u>	
205.373		
Short-term liabilities	-2.193	
Liquidity surplus = working capital	<u>203.180</u>	
Established for the long term		
Financed with on the long term available assets	<u>203.180</u>	
Financing		
Net assets	<u>203.180</u>	



HUMAN VACCINES PROJECT
DECODING THE IMMUNE SYSTEM

Summary financial information

31-12-2021
€

Assets

Current assets

Receivables	-
Cash and cash equivalents	<u>205.373</u>
Total assets	<u>205.373</u>

Equity and liabilities

Net assets	203.180
Short-term liabilities	<u>2.193</u>
Total equity and liabilities	<u>205.373</u>

2021

€

Benefits	81.300
Total of net result	-71.357
Total of net result	-71.357
Net assets	203.180